Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an announcement.
Alligator Bioscience announced the final results of its OPTIMIZE-1 trial, showcasing the potential of its lead drug candidate, mitazalimab, in treating metastatic pancreatic cancer. The trial results indicate promising clinical activity, with mitazalimab combined with standard chemotherapy demonstrating durable responses and favorable survival rates compared to historical benchmarks. These findings support the advancement of mitazalimab into a pivotal Phase 3 trial, potentially offering a transformative treatment option for pancreatic cancer, a field with limited therapeutic advancements. The company is preparing to initiate this trial with a partner, marking a significant step forward in its development pipeline.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, focusing on developing clinical-stage tumor-directed antibody drugs. The company targets the CD40 receptor to enhance T cell priming and counteract the immunosuppressive tumor microenvironment, aiming to provide significant benefits for cancer patients across various cancer types. Alligator Bioscience is listed on Nasdaq Stockholm under the ticker ATORX.
YTD Price Performance: -80.76%
Average Trading Volume: 465,188
Technical Sentiment Signal: Sell
Current Market Cap: SEK141M
See more data about ATORX stock on TipRanks’ Stock Analysis page.